(2R,6R)-Hydroxynorketamine

Phase 2

NNational Center for Complementary and Integrative Health (NCCIH)

(2R,6R)-Hydroxynorketamine is one of 31 therapeutic programs targeting Suicide. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

SuicideRecruiting

SuicidePhase 2

Recruiting

Competition

Competitive Landscape

40 competitors in Suicide

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

6 2

Estrace

Spravato

2 4

Paxil

SSebela Pharmaceuticals Development LLC

Approved

1 5

Lexapro

AbbVie

Phase 3

1 6

Celexa

AbbVie

Phase 3

1 7

Micronized Progesterone

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Approved

1 8

Wellbutrin

GGlaxo Dba Glaxosmithkline

Phase 3

2 9

Suboxone

IIndivior Inc.

Phase 3

1 10

Zoloft

VViatris Specialty LLC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Suicide

NCT06511908

Q4 2031

Phase 2Not yet recruiting

Study completion

NCT07504601

Clinical

Trials by Indication[1]

Suicide1 trial

An Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

Recruiting·NNational Institute of Mental Health (NIMH)·Phase 2·NCT06511908·50 enrolled

Unspecified1 trial

Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers

Not yet recruiting·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2·NCT07504601·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for (2R,6R)-Hydroxynorketamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for (2R,6R)-Hydroxynorketamine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Center for Complementary and Integrative Health (NCCIH) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: NNational Center for Complementary and Integrative Health (NCCIH)

(2R,6R)-Hydroxynorketamine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2031

Trials by Indication[1]

Suicide1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News